Wiskott-Aldrich Syndrome: Diagnosis, Clinical and Laboratory Manifestations, and Treatment

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 84-90

  Ochs, Hans D ^a   Filipovich, Alexandra H ^b   Veys, Paul ^c   Cowan, Morton J ^d   Kapoor, Neena ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hematopoietic stem cell transplantation; Reduced intensity conditioning regimen; Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; X linked thrombocytopenia

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MITOMYCIN C; RITUXIMAB; THYMOCYTE ANTIBODY; TREOSULFAN; WISKOTT ALDRICH SYNDROME PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CYTOPENIA; DISEASE COURSE; EVENT FREE SURVIVAL; GENE FUNCTION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; INCIDENCE; MISSENSE MUTATION; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; REVIEW;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TREATMENT OUTCOME; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 64749097074     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.007     Document Type: Article

References (31)

1. Wiskott A. Familiärer, angeborener morbus werlhofii?. Monatsschr Kinderheilkd 68 (1937) 212-216
2. Aldrich R.A., Steinberg A.G., and Campbell D.C. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 13 (1954) 133-139
3. Ochs H.D., and Rosen F.S. The Wiskott-Aldrich syndrome. In: Ochs H.D., Smith C.I.E., and Puck J.M. (Eds). Primary Immunodeficiency Diseases: A Molecular and Genetic Approach (2007), Oxford University Press, New York 454-469
4. Notarangelo L.D., Miao C.H., and Ochs H.D. Wiskott-Aldrich syndrome. Curr Opin Hematol 15 (2008) 30-36
5. Notarangelo L.D., Mazza C., Giliani S., et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 99 (2002) 2268-2269
6. Jin Y., Mazza C., Christie J.R., et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 104 (2004) 4010-4019
7. Machesky L.M., and Insall R.H. Scar1 and the related Wiskott-Aldrich syndrome protein, WASP, regulate the actin cytoskeleton through the Arp2/3 complex. Curr Biol 8 (1998) 1347-1356
8. Devriendt K., Kim A.S., Mathijs G., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 27 (2001) 313-317
9. Ochs H.D., Slichter S.J., Harker L.A., et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 55 (1980) 243-252
10. Westerberg L., de la Fuente M.A., Wermeling F., et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood (Sep 4, 2008) (Epub ahead of print)
11. Meyer-Bahlburg A., Becker-Herman S., Humblet-Baron S., et al. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood (Sep 4, 2008) (Epub ahead of print)
12. Orange J.S., Ramesh N., Remold-O'Donnell E., et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and co-localizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 99 (2002) 11351-11356
13. Calle Y., Chou H.C., Thrasher A.J., et al. Wiskott-Aldrich syndrome protein and the cytoskeletal dynamics of dendritic cells. J Pathol 204 (2004) 460-469
14. Sullivan K.E., Mullen C.A., Blaese R.M., et al. A multi-institutional survey of the Wiskott-Aldrich syndrome. J Pediatr 125 (1994) 876-885
15. Shcherbina A., Rosen F.S., and Remold-O'Donnell E. Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol 106 (1999) 875-883
16. Dupuis-Girod S., Medioni J., Haddad E., et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111 (2003) e622-e627
17. Kim A.S., Kakalis L.T., Abdul-Manan N., et al. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404 (2000) 151-158
18. Sasahara Y., Rachid R., Byrne M.J., et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 10 (2002) 1269-1281
19. Moulding D.A., Blundell M.P., Spiller D.G., et al. Unregulated actin polymerization by WASP causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med 204 (2007) 2213-2224
20. Ochs H.D., and Thrasher A.J. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117 (2006) 725-738
21. Konno A., Wada T., Schurman S.H., et al. Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood 103 (2004) 676-678
22. Bach F.H., Stone J.V., Tomany S.C., et al. Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 292 (1968) 1364-1366
23. Bortin M.M., Bach F.H., van Bekkum D.W., et al. 25th anniversary of the first successful allogeneic bone marrow transplants. Bone Marrow Transplant 14 (1994) 211-212
24. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 (2001) 1598-1603
25. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and the European Group for Blood Blood and Marrow Transplantation. Blood 111 (2008) 439-445
26. Antoine C., Muller S., Cant A., et al. Long-term survival and haematopoietic stem cell transplantation for immunodeficiencies: a survey of the European experience 1968-1999. Lancet 361 (2003) 553-560
27. Muñoz A., Olivé T., Martinez A., et al. Transplantation in Children (GETMON). Allogeneic hematopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol 24 (2007) 393-402
28. Amrolia P., Gaspar B., Hassan A., et al. Non-myeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96 (2000) 1239-1246
29. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplant in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105 (2005) 879-885
30. Satwani P., Cooper N., Rao K., et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 41 (2008) 73-182
31. Greystoke B., Bonanomi S., Carr T.F., et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 142 (2008) 257-262